British startup Shift Bioscience has successfully raised $16 million in seed funding to advance its AI-driven platform aimed at identifying genes that can rejuvenate aging cells. The funding will support the development of epigenetic reprogramming technologies that focus on safe rejuvenation genes, minimizing the risks associated with traditional methods like Yamanaka factors. Shift Bioscience's innovative approach utilizes AI cell simulations to explore the genetic factors that contribute to cellular rejuvenation and combat age-related diseases. The funding round has garnered positive attention, with investors highlighting the team's intelligence and determination in the biotech field.